Manufacturing & Supply Chain

Bristol-Myers buys rights to fibrosis drug for up to $1.25bn

 Breaking News

Bristol-Myers buys rights to fibrosis drug for up to $1.25bn

Bristol-Myers buys rights to fibrosis drug for up to $1.25bn
August 31
14:44 2015
Spread the love

Bristol-Myers Squibb Co. is paying up to $1.25 billion for the rights to a developing fibrosis drug in a deal that also gives it the right buy drug developer Promedior Inc.

Bristol-Myers will buy worldwide rights to drug candidate PRM-151, currently in midstage development as a treatment for the lung condition idiopathic pulmonary fibrosis and bone marrow disorder myelofibrosis. The drug candidate has already been granted special FDA designations allowing for speedier development and a faster review process.

Under the terms of the deal, Bristol-Myers Squibb will make an upfront payment of $150 million as consideration to buy rights to the drug candidate and Promedior. Total payments could reach up to $1.25 billion and Bristol-Myers can exercise its right to buy Promedior upon completion of future clinical trials.

About Author

admin

admin

Related Articles

Follow me on Twitter

New Subscriber

    Subscribe Here



    Advertisements
























    National Manufacturing Conference & Exhibition 2020

    NIBRT Springboard Success Stories